Chronic kidney disease kills more than 1M people annually worldwide
Chronic kidney disease has been described as a " global killer in plain sight " by the authors of a new analysis estimating the prevalence of the condition.
Conclusions: Our study suggests that elevated serum PAPP-A is associated with the risk of all-cause mortality in patients with CKD. PMID: 32051700 [PubMed]
ConclusionsThe study demonstrated the worse prognostic value of sudden renal function decline in HF patients and pointed to those with more future risk who require review of treatment and closer follow ‐up.
This study used a murine model of adenine-induced renal failure to investigate whether or not SCFAs can prevent the progression of renal damage. We also examined whether or not these FFA2 and FFA3 proteins have some roles in this protective mechanism in vivo. Immunohistochemical analyses of mouse kidneys showed that FFA2 and FFA3 proteins were expressed mainly in the distal renal tubules and collecting tubules. First, we observed that the administration of propionate mitigated the renal dysfunction and pathological deterioration caused by adenine. Consistent with this, the expression of inflammatory cytokines and fibrosis-...
(Reuters Health) - People who get plenty of physical activity may be less likely than their more sedentary counterparts to develop chronic kidney disease, a recent study suggests.
CONCLUSION: the health-related quality of life of people with chronic kidney disease after transplantation ranged from good to excellent. The presence of depression was not identified. The relationship of data indicates that the higher the quality of life, the better the self-esteem assessment. PMID: 32049246 [PubMed - in process]
Publication date: Available online 13 February 2020Source: The LancetAuthor(s): Boris Bikbov, Caroline A Purcell, Andrew S Levey, Mari Smith, Amir Abdoli, Molla Abebe, Oladimeji M Adebayo, Mohsen Afarideh, Sanjay Kumar Agarwal, Marcela Agudelo-Botero, Elham Ahmadian, Ziyad Al-Aly, Vahid Alipour, Amir Almasi-Hashiani, Rajaa M Al-Raddadi, Nelson Alvis-Guzman, Saeed Amini, Tudorel Andrei, Catalina Liliana Andrei, Zewudu AndualemSummaryBackgroundHealth system planning requires careful assessment of chronic kidney disease (CKD) epidemiology, but data for morbidity and mortality of this disease are scarce or non-existent in many...
Publication date: Available online 13 February 2020Source: The LancetAuthor(s): Paul Cockwell, Lori-Ann Fisher
Conclusion: Evolocumab may have a beneficial effect on renal involvement in patients with CCE. PMID: 32046605 [PubMed - in process]
Conclusions. In a context of person-centered medicine, autonomy, beneficence and non-maleficence should weight more than economic justice. While ethical discussions are not aimed at finding “the right answer” but asking “the right questions”, this example can raise awareness of the importance of including an ethical analysis in the choice of “economically relevant” drugs.
This study aimed to examine the association between the mode of dialysis or the values of sclerostin or DKK1 and carotid-femoral pulse wave velocity (cfPWV) in ESRD patients. There were 122 HD and 72 PD patients enrolled in this study. By a validated tonometry system, cfPWV was measured and then segregated patients into values of >10 m/s as the high central arterial stiffness (AS) group and values ≤ 10 m/s as the control group. Serum levels of sclerostin and DKK1 were measured using a commercial enzyme-linked immunosorbent assay kit. Possible risk factors for the development of AS were analyzed by logistic regres...